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phe annual congress of the European Society of Cardiology
ESC) was held in Vienna, Austria, September 1 to 5, 2007.
he total attendance was close to 30,000 participants from
36 different countries. Excellent new congress facilities
osted 186 prearranged sessions (28 meeting rooms running
n parallel), including several joint sessions organized in
ollaboration with other societies, including the American
ollege of Cardiology (ACC) and the American Heart
ssociation (AHA). A total of 9,691 abstracts from 92
ifferent countries were submitted, and 3,501 (36%) were
elected for presentation, including 29% dedicated to basic
cience.
rom the *Aarhus University Hospital, Skejby, Aarhus, Denmark; †Vienna General
ospital/Medical University of Vienna, Vienna, Austria; ‡Zentrum Innere Medizin,
bteilung Kardiologie, Hannover, Germany; §Institut fuer Hertzinfarktforschung
udwigshafen an der Universitaet Heidelberg, Heidelberg, Germany; Universita-
tsklinikum Schleswig-Holstein, Campus, Luebeck, Germany; ¶Centre Hospitalier
niversitaire Vaudois, Lausanne, Switzerland; #Athens University Hospital Attikon,
thens, Greece; **Karolinska University Hospital, Stockholm, Sweden; ††C.H.U. du
art-Tilman, Universite de Liege, Liege, Belgium; ‡‡University of Leuven (KUL),
euven, Belgium; §§Erasmus Medical Center, Rotterdam, the Netherlands;  Lei-
en University Medical Center, Leiden, the Netherlands; and the ¶¶Royal Brompton
ospital, London, United Kingdom. Dr. Fox is president of the European Society of
ardiology (ESC). Dr. Bax is the ESC Congress Program Committee Chair. Dr.
ristensen has received lecture fees from and is on the advisory board of AstraZeneca,
ristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Nycomed, and Sanofi-Aventis.
r. Eeckhout has received research grants from Boston Scientific, Medtronic, Abbott
ascular, B Braun, and Cordis. Dr. Gitt has received lecture fees and grants from and
s on the advisory board of Merck Sharpe & Dohme, Bristol-Myers Squibb,
anofi-Aventis, Essex Pharma, Schering-Plough, Amgen, Abbott Vascular, Eli Lilly,
nd Pfizer. Dr. Linde is a consultant to Medtronic Inc. Dr. Poldermans has received
esearch grants from Merck and Novartis. Dr. Schunkert has received lecture fees
rom and is on the advisory board of Merck, Sharpe & Dohme/Essex Pharma,
ovartis, Sanofi-Aventis, AstraZeneca, Pfizer, and Nycomed. Dr. Fox has received
esearch grants and honoraria from Servier. Dr. Bax has received research grants from
E Healthcare, Bristol-Myers Squibb Medical Imaging, St. Jude, Medtronic, ands
oston Scientific.
Manuscript received October 25, 2007; accepted October 25, 2007.The theme of the meeting was “Heart Failure.” The
athophysiology, diagnosis, and management of patients
ith heart failure (HF) were addressed in 37 pre-arranged
essions and 16 scientific abstracts sessions. In this review,
he contributions related to HF are discussed first, followed
y the Hotlines and the Euro Heart Survey Program.
hereafter, a summary of the most important contributions
resented at the different sessions is provided.
eart Failure
eart failure is a major cause of hospital stays in the
estern world, and many patients are readmitted or suffer
rom high mortality after discharge. A large registry fol-
owed 48,612 patients with acute HF after discharge (1). A
re-specified sample of 10% was followed for 60 to 90 days
nd investigated for coronary revascularization. Patients
ith ischemic etiology of HF had a significantly worse
utcome at 90 days as compared with nonischemic HF,
lthough patients with ischemic HF who underwent coro-
ary revascularization had similar survival to patients with
onischemic HF. These observations underscore that eval-
ation of coronary status in patients admitted to the hospital
ith acute HF is crucial.
A pilot study investigated the effects of chronic use of
ildenafil on exercise capacity and reactive pulmonary hy-
ertension in patients with HF in a controlled clinical trial,
nrolling 19 HF patients with New York Heart Association
lass I to III function, with left ventricular ejection fraction
LVEF) 40%, and who were on optimized medical
herapy (2). Peak oxygen uptake increased (13%) and
ulmonary pressure decreased (32%) significantly in the
ildenafil group.
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Highlights of the 2007 ESC Scientific Sessions December 18/25, 2007:2421–30Peripartum cardiomyopathy is a rare but potentially
evastating disease of unknown etiology. A recent report
as shown that a cathepsin D-cleaved 16 kDa form of
rolactin can mediate peripartum cardiomyopathy and that
nhibition of prolactin release by bromocriptine in a mouse
odel can prevent the emergence of the disease. Forster et
l. (3) reported that the addition of bromocriptine to
tandard HF therapy improved outcomes in patients with
revious peripartum cardiomyopathy. Although LVEF con-
inued to decrease between post-delivery and follow-up in
atients on standard medical care, a significant improve-
ent in LVEF was observed in the bromocriptine group.
Weight loss and leanness simultaneously predicted poor
rognosis in a broad spectrum of HF patients (4). More-
ver, recent weight loss strongly predicted short-term mor-
ality risk. It remains unclear whether weight loss in HF
atients is due to cachexia, impaired/reduced food intake, or
ehydration from fluid loss. Yet, good management should
losely monitor weight change in HF patients.
There is compelling evidence that the adult heart has
esident cardiac stem cells. However, the functional prop-
rties of these cells in HF patients are unknown. Marcon et
l. (5) evaluated both donor and recipient human hearts and
solated multipotent adult stem cells and reported that adult
tem cells obtained from failing hearts had impaired func-
ion, including impaired cardiomyocyte and endothelial
ifferentiation and reduced migration. Thus, the resident
ardiac stem cell reservoir is functionally impaired in patho-
ogical processes, which might limit therapeutic use of these
esident cardiac stem cells.
uro Heart Survey
he Euro Heart Survey Program includes repeated surveys
nd ongoing registries; data from current surveys and
egistries were presented in 5 symposia concerning HF,
econdary prevention, acute coronary syndromes (ACS),
ercutaneous coronary intervention (PCI), and diabetes.
F. The Euro Heart Survey on Heart Failure II enrolled
,580 patients with acute HF to document adherence to
SC guidelines on diagnosis and treatment of acute HF.
he majority of patients (85%) had echocardiography in the
cute phase, but only 50% of patients with ACS as the
nderlying cause for acute HF underwent coronary angiog-
aphy. At discharge, 71% of patients received angiotensin-
onverting enzyme (ACE) inhibitors, 61% beta-blockers,
nd 48% aldosterone blockers with large variations between
he different centers. The use of class IA-recommended
CE inhibitors as well as beta-blockers was associated with
significant decrease in 1-year mortality. Moreover, analysis
f the Euro Heart Survey data identified the following
redictors of short-term mortality: advanced age, low sys-
olic blood pressure, renal failure, peripheral hypo-
erfusion, ACS as precipitating factor, and pulmonary
dema. A risk score including these parameters was pre- cented, allowing discrimination of patients with a low
0.5%) to very high risk (22%) of death.
econdary prevention. Data on clinical reality of second-
ry prevention in Europe were presented comparing the
urrent results of EUROASPIRE (European Action on
econdary Prevention through Intervention to Reduce Events)
II with those of the previous surveys EUROASPIRE I and II,
ith time trends in the management of lifestyle and risk
actors like blood pressure, lipids, and diabetes as well as
rug treatment over the last 12 years. The results regarding
he time trends in lifestyle were disappointing, with no
hange in smoking and a dramatic increase in obesity
one-third of patients had a body mass index 30 kg/m2),
s well as in waist circumference (50% of patients being
entrally obese). The prevalence of diabetes increased to
3%. No improvement in blood pressure management could
e documented, with 50% of patients not reaching the
ecommended target of 140/90 mm Hg. Lipid management
ramatically improved, owing to widespread use of statins,
ut only 53% of patients reached the target of 2.5 mmol/l
or low-density lipoprotein (LDL) cholesterol. It seems that
atients would rather take pills than change their lifestyle.
ore professional support for lifestyle changes and risk-
actor modification by comprehensive prevention and reha-
ilitation programs is needed.
CS. Following the Euro Heart Surveys on ACS-I in
000 and ACS-II in 2004, an ACS-Registry is currently
ngoing. Data on treatment and outcome of ACS patients
dmitted to cardiology versus internal medicine depart-
ents were presented. Patients admitted to a cardiology
epartment were younger, less often female, and more often
resented with ST-segment elevation ACS than with non–
T-segment elevation ACS. Primary reperfusion rates were
igher, both for ST-segment and for non–ST-segment
levation ACS, whereas no significant differences were
bserved in use of adjunctive medical therapy, including
spirin, clopidogrel, beta-blockers, statins, and ACE inhib-
tors. Despite the higher rate of ST-segment elevation ACS,
he in-hospital mortality was lower in cardiology versus
nternal medicine departments (3.8% and 5.5%, respec-
ively), probably related to the use of primary PCI in
ardiology departments. Another analysis demonstrated the
mpact of renal failure on treatment and outcome of ACS.
atients with renal failure were frequently older, had dia-
etes, and a history of PCI or coronary artery bypass
urgery. They more often presented with non–ST-segment
levation ACS, less often underwent coronary angiography
s compared with patients without renal failure, and more
ften had 3-vessel disease but less often received reperfusion
reatment. Hospital mortality was doubled in patients with
enal failure, a consistent finding in the ACS-I and -II
urveys and the ACS-Registry.
CI. The Euro Heart Survey on PCI enrolled 14,575
onsecutive patients in 134 centers of 39 ESC member
ountries between June 2005 and January 2006, and the
urrently ongoing PCI-Registry additionally enrolled
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December 18/25, 2007:2421–30 Highlights of the 2007 ESC Scientific Sessions9,007 patients since May 2006. Preliminary data of the
CI-Registry were presented to compare practice in 2007
nd 2005 (PCI-Survey). There were no changes in baseline
haracteristics with a mean age of 64 years, 75% male
atients, and 25% diabetic patients. Patients treated with
CI in 2007 had a higher prevalence of prior infarction,
rior PCI, and history of HF. About two-thirds of patients
nderwent PCI for ACS, with no significant changes
etween 2005 and 2007. More patients received multi-
esion and multivessel treatment in 2007, reflecting more
omplete revascularization as compared with 2005. More
ifurcation lesions were treated, but there was no change in
he overall use of drug-eluting stents (DES) (45% of all
tents). Only 50% of patients undergoing primary PCI
eceived glycoprotein IIb/IIIa receptor blockers without any
hange over the years, whereas a small increase in the use of
lycoprotein IIb/IIIa receptor blockers could be docu-
ented for PCI in non–ST-segment elevation ACS (32.5%
s. 26.3%). The overall complication rate remained low,
ith a mortality of 1.8%.
iabetes. Analyses of different surveys within the Euro
eart Survey Program presented the burden of diabetes on
ardiovascular disease in Europe. In patients with ACS,
iabetic patients less often received reperfusion and adjunc-
ive medical therapy and had higher in-hospital mortality
13.5% vs. 6.8%) in 2007. In the Euro Heart Survey on HF,
iabetes was present in about 30% to 40% of patients with
cute and chronic HF. Diabetes was an independent risk
actor for 1-year mortality in acute and new as well as
hronic decompensated HF. In the Euro Heart Survey on
table angina, 17% of patients had known diabetes. Diabetes
as independently associated with more severe coronary
rtery disease (CAD) on angiography and with adverse
ong-term prognosis.
otlines and Clinical Trial Updates
he 5-year follow-up results of the getABI (German
pidemiological Trial Ankle-Brachial Index) registration of
rimary care patients with peripheral arterial disease (PAD)
evealed a high mortality. In 6,880 patients (65 years from
44 primary care centers) ankle-brachial index was assessed
o determine the presence and severity of PAD. The
ncidence of PAD was 21%, with more than 50% being
symptomatic. In patients with severe PAD the 5-year
ortality was 50%, predominantly because of late cerebro-
ardiovascular events. There was a correlation between the
everity of PAD and prognosis; importantly there was no
ifference between asymptomatic and symptomatic PAD
atients.
Diabetes mellitus and hypertension are well-known car-
iovascular risk factors. In diabetic patients, the ESC
uidelines recommend a target blood pressure below 130/80
m Hg. The ADVANCE (Action in Diabetes and Vas-
ular Disease-PreterAx and DiamicroN MR Controlled
valuation) study, including 11,140 patients, was designed yo determine the beneficial effects of blood-pressure lower-
ng on cardiovascular events. This randomized, placebo-
ontrolled study used a fixed combination of perindopril-
ndapamide on top of current therapy, irrespective of pre-
reatment blood pressure. The average pre-treatment blood
ressure was 145/81 mm Hg, indicating a mixed population
f mild hypertensives and normotensives. In the treatment
rm, systolic and diastolic blood pressure dropped on
verage 5.6 and 2.2 mm Hg, respectively. During a 4.3-year
ollow-up, there was 14% reduction of all-cause mortality (p
0.025), with 18% reduction of cardiovascular deaths (p 
.027) in the treatment arm. There was no difference
etween patients with and without hypertension.
Aliskiren is a recently introduced oral renin inhibitor.
he safety and efficacy effects of aliskiren on top of ACE
nhibitors, angiotensin receptor blockers, or beta-blockers
ere evaluated in a placebo-controlled study, randomizing
02 patients with stable heart failure to aliskiren or placebo
dded to standard therapy. The primary end point of the
tudy was safety, regarding renal function, symptomatic
ypotension, and hyperkalemia. During 12 weeks of follow-
p, there were no safety concerns regarding the new study
rug; renal function and serum potassium showed no
ignificant differences. Aliskiren effectively inhibited plasma
enin activity. During the short study period, no difference
n LVEF was observed. Brain natriuretic peptide (BNP)
evels were significantly reduced (12.2 vs.61 pg/ml, p
.05).
The effects of vitamin B supplements to lower homocys-
eine levels were studied in WENBIT (Western Norway
-vitamin Intervention Trial). A total of 3,090 patients
ith proven CAD were randomized to vitamin B therapy,
ncluding 4 groups (vitamin B6; folic acid plus vitamin B12;
combination of vitamins B6, B12, and folic acid; and
lacebo). During a mean follow-up of 38 months, no
ifference in the primary outcome (composite of all-cause
ortality, nonfatal infarction, unstable angina, and stroke)
as observed in patients randomized to vitamin B supple-
ents. Vitamin B supplementation is presently not recom-
ended as secondary prevention for CAD.
The 3-year follow-up of the DANAMI-2 (Second Dan-
sh Acute Myocardial Infarction) trial showed that the
nitial benefit of transferal for primary PCI compared with
brinolysis was sustained. One-year follow-up in the
TEEPLE (Safety and Efficacy of Enoxaparin in Percuta-
eous Coronary Intervention Patients) trial showed that
noxaparin was superior to unfractionated heparin in pa-
ients undergoing elective PCI, and similarly in the
xTRACT-TIMI (Enoxaparin and Thrombolysis Reper-
usion for Acute Myocardial Infarction Treatment—
hrombolysis In Myocardial Infarction)-25 study, the ben-
fit of enoxaparin compared with unfractionated heparin
fter fibrinolysis in patients with ST-segment elevation
yocardial infarction (STEMI) was still present after 1ear.
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Highlights of the 2007 ESC Scientific Sessions December 18/25, 2007:2421–30The PRAGUE-8 trial randomized patients undergoing
iagnostic angiography (n  1,028) to routine pre-loading
ith clopidogrel (600 mg) before angiography or selective
n-lab administration for PCI patients only. There was no
ifference in the primary ischemic end point (death, infarc-
ion, stroke, and reintervention within 7 days), even in
onselective patients who underwent PCI compared with
elective control subjects (1.3% vs. 2.2%). Nonselective
herapy induced significantly more bleeding complications
7.2% vs. 0.7%). Therefore, routine clopidogrel administra-
ion before diagnostic angiography cannot be recom-
ended. It increased bleeding risk without benefit on
schemic periprocedural complications.
In the CARESS (Combined Abciximab Reteplase Stent
tudy in Acute MI) trial, 600 patients with acute STEMI
ere all treated with one-half-dose reteplase plus abciximab
nd then randomized to transferal for immediate primary
CI or medical therapy (with rescue PCI if necessary). The
rimary outcome was the composite of all-cause mortality,
einfarction, or refractory ischemia at 30 days. In the group
andomized to immediate transfer, there was a significant
7% reduction in the primary end point. This trial confirms
he results of other trials suggesting that fibrinolytic therapy
n STEMI should be followed by early coronary angiogra-
hy with PCI.
The FINESSE (Facilitated Intervention with Enhanced
eperfusion to Stop Events) trial randomized 2,452 patients
ith STEMI referred for primary PCI to upstream one-
alf-dose reteplase plus abciximab, upstream abciximab, or
bciximab administered in the catheterization laboratory.
here was no significant difference in the primary end point
composite of death, repeat hospital stay for HF, resusci-
ated ventricular fibrillation [48 h after randomization],
nd cardiogenic shock at 90 days) among the 3 groups. The
ccurrence of Thrombolysis In Myocardial Infarction major
nd minor bleeding was significantly lower in the in-lab
bciximab group, and therefore facilitation neither with
ne-half-dose reteplase plus abciximab nor with abciximab
lone can be recommended in primary PCI.
The Swedish nationwide PCI registry presented 4-year
linical outcomes in about 180,000 procedures (37,000
ES implanted). No differences in mortality and infarc-
ion were observed between bare-metal stents (BMS) and
ES. Data from the GRACE (Global Registry of Acute
oronary syndromEs) registry of patients with ACS were
lso presented. Patients with ACS with DES had a
ignificantly lower in-hospital death rate (1.1%) than
MS patients (2.7%), although mortality of the 2 groups
as identical at 6 months. Between 6 months and 2 years,
owever, there was a significantly higher reinfarction rate
n DES as compared with BMS (2.9% vs. 5.4%, p 
.05). Mortality, in contrast, was similar between 6
onths and 2 years (DES 4.8%, BMS 4.6%) in the ACSatients. snterventional Cardiology
rug-eluting stent safety was also a hot topic in the abstract
essions. A 4-year update of the Bern–Rotterdam DES
egistry was presented (6). Investigators performed 100%
ES in consecutive patients between 2002 and 2005 (n 
,146) and kept a permanent track on angiographic stent
hrombosis. At 4 years, it was concluded that the cumulative
ncidence of stent thrombosis continues to rise at 3.3%, with
slope indicating an annual risk of 0.6%. Further follow-up
f this patient cohort is thus warranted.
The French Left Main Taxus registry reported on the
afety and efficacy of DES in this specific lesion subset (7).
n 291 patients treated at 4 centers, 0.7% in-hospital
ortality (predicted 6.4% according to the logistic Euro-
core) and 5.2% cardiac mortality at 2 years were presented.
he need for revascularization at follow-up was only 7.9%.
utch investigators presented follow-up data of a random-
zed, controlled trial on BMS versus DES in acute infarc-
ion (8). In 619 patients, there was no difference in the
rimary end point of death, infarction, and the need for
eintervention at 2-year follow-up (15.4% BMS vs. 11.1%
ES).
A Polish trial addressed the practical issue of immediate
otal percutaneous revascularization versus staged interven-
ion in acute infarction patients with multivessel disease (n
208) (9). At 1-year follow-up, there was no difference in
rimary end point (absolute change in LVEF) between both
roups but also no difference in adverse events, and a 1-stage
pproach seemed more cost-effective.
Finally, the results of the first-in-man use of a fully
ioabsorbable everolimus-eluting stent (polylactic acid poly-
er backbone) were presented (10). A total of 30 patients
ith single, de novo lesions were treated, including
ollow-up angiography and intravascular ultrasound. Over-
ll, a late luminal loss of 0.44  0.35 mm was reported,
esulting in a binary restenosis rate of 11.5%. Only 1 acute
dverse event occurred (partial stent dislodgement). Lumi-
al reduction was due to remodeling and recoil (mean
1.7%) and discrete neointimal hyperplasia (mean 5.5%).
cute Coronary Syndromes
on–ST-segment elevation myocardial infarction
NSTEMI) ACS. The new ESC guidelines on NSTEMI
CS recommend early angiography (within 72 h) and
ubsequent revascularization as appropriate in high-risk
atients with ACS. Data from the GRACE registry showed
hat in NSTEMI ACS patients undergoing angiography,
nly 30% had angiography performed within 72 h as
ecommended (11). A study from Korea confirmed that the
RACE risk score is a useful predictor of mortality in
atients with ACS (12). Data from a prospective multi-
enter cohort study showed that Thrombolysis In Myocar-
ial Infarction risk score and plasma levels of interleukin
IL)-6 at admission were the only independent markers of
erious cardiovascular events at 30 days (13).
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December 18/25, 2007:2421–30 Highlights of the 2007 ESC Scientific SessionsPost hoc analysis of data from the ACUITY (Acute
atheterization and Urgent Intervention Triage strategY)
rial showed that the occurrence of baseline anemia is
ssociated with an increased risk of early death, infarction,
nd major bleeding in patients with moderate and high-risk
CS (14). Premature discontinuation of clopidogrel in
atients presenting with NSTEMI had a deleterious effect
haracterized by occurrence of major cardiovascular events
t a rate higher than in patients treated with aspirin alone (15).
TEMI. For patients with STEMI, the mortality record in
French registry dramatically decreased over the past 10
ears. This decrease is likely related to a broader use of
eperfusion therapy and other recommended therapeutic
trategies, such as statins, beta-blockers, and low-molecular-
eight heparin during the first days of the acute episode
16). Registry data from Portugal showed that the pre-
ospital delay for STEMI is too long, particularly in elderly
atients, in diabetic patients, and in patients with a history
f angina (17). Results of the Czech National PCI Registry
howed that every 15-min delay in door-to-balloon time
nd every 1-h delay in total ischemia time significantly
ncreased 30-day mortality, emphasizing the need for im-
ediate PCI (18).
French registry data showed that pre-hospital thrombol-
sis combined with high use of subsequent PCI is associated
ith excellent early and mid-term outcomes (19). The use
f thrombectomy devices in primary PCI was evaluated in a
eta-analysis of 7 randomized trials. Myocardial reperfu-
ion evaluated as ST-segment resolution and myocardial
lush grade was reduced in the thrombectomy group (20). A
tudy from Canada showed that, in carefully selected pa-
ients who were stable after primary PCI in a tertiary PCI
ospital, immediate re-transfer to the referring hospital is
afe and feasible (21). A meta-analysis of trials on STEMI
atients presenting after 12 h of symptoms showed that late
evascularization of the occluded artery with PCI might
mprove LV systolic function and prevent remodeling (22).
cute Cardiac Care
imited data are available about the management of car-
iogenic shock in elderly patients. Gasior et al. (23) pre-
ented the in-hospital outcomes of 4,518 patients with acute
nfarction and cardiogenic shock on admission who were
egistered in the prospective Polish ACS registry between
003 and 2006. An early invasive strategy in elderly patients
75 years) resulted in lower in-hospital mortality compa-
able to younger patients.
Recent data suggest that inappropriate vasodilation might
ccur in cardiogenic shock. In 27 patients presenting with
ardiogenic shock and inappropriate vasodilation, an
rginine-vasopressin infusion (2 to 4 IU/h) was used to
upport circulation; this approach significantly improved
emodynamic status and diuresis (24).
Advances in cardiopulmonary resuscitation were alsoresented. It has recently been suggested that a simpler form sf cardiopulmonary resuscitation could be as effective as
tandard cardiopulmonary resuscitation. Among 11,275 pa-
ients who reported to the Swedish Cardiac Arrest Registry
etween 1990 and 2005, survival was significantly lower
mong those who received mouth-to-mouth ventilation
nly (25). However, there was no significant difference in
-month survival between patients who received standard
ardiopulmonary resuscitation (survival 7.2%) compared
ith those who received chest compression only (survival
.7%).
In the international resuscitation guidelines, mild hypo-
hermia is recommended after return of spontaneous circu-
ation from cardiac arrest to improve neurological recovery.
olfrum et al. (26) investigated the feasibility of mild
ypothermia in 16 patients with STEMI and subsequent
ardiac arrest who needed “acute” PCI. Hypothermia was
nitiated before patients were transported to the cardiac
atheterization laboratory. When compared with an histor-
cal control group, initiation of mild hypothermia did not
elay PCI, and patients tended to have lower 6-month
ortality with an improved neurological outcome. Early
dministration of selenium after cardiopulmonary resuscita-
ion was evaluated in another study; this approach improved
eurological outcome without a 6-month survival benefit (27).
ypertension and Risk Factors
idely discussed during the congress were the new 2007
SC/European Society of Hypertension guidelines for the
anagement of hypertension, which define “hypertension”
s blood pressure levels between 130 and 140 mm Hg
ystolic and 80 and 90 mm Hg diastolic, taking comorbidi-
ies and other risk factors into consideration. Indeed,
atients with diabetes, renal disease, or manifestations of
therosclerosis should be diagnosed at levels below 140 mm
g and thus be treated with antihypertensive drugs.
Similarly, the threshold at which cholesterol-lowering
educes cardiovascular events is under debate. The IDEAL
Incremental Decrease in End Points through Aggressive
ipid Lowering) Investigators presented a post hoc analysis
hat suggests no further risk reduction beyond LDL lower-
ng 89 mg/dl in patients with previous infarction (28). At
hat threshold level, a further decrease of LDL levels was
ot associated with further cardiovascular benefits. Rather,
n subjects with low LDL under optimal statin treatment,
ther modifiable risk factors such as arterial hypertension
nd diabetes determined future risk of cardiovascular events.
The ESC congress also introduced novel genetic and
roteomic risk factors. Genome-wide association studies
evealed that a substantial proportion of the inherited risk
or infarction is located at chromosomes 9p21.3, 6q25.1,
nd 2q36.3. Another test might be of future relevance for
atients with manifestation of atherosclerosis in the carotid
rteries. A careful proteomic tissue profiling on a carotid
therectomy specimen predicted future infarction, stroke, or
ymptomatic PAD events during long-term follow-up in
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laque material (29). Eventually, these data might provide
ew insights in the pathogenesis, progression, and hopefully
revention of atherosclerosis.
rrhythmias and Pacing
arious studies were dedicated to atrial fibrillation (AF).
ne study evaluated whether transient AF in the setting of
nferior STEMI with preserved LV function was linked to
uture risk of AF and stroke (30). All patients (59 transient
F, 372 sinus rhythm) were discharged with antiplatelet
herapy. At 12 months’ follow-up, patients with transient
F had a higher recurrence rate (22% vs. 1.3%) and higher
ncidence of ischemic stroke (10.2% vs. 1.8%) than sinus
hythm patients but total mortality was similar (5.6% vs.
.8%). This finding implies that oral anticoagulation should
e considered in patients with inferior infarction, preserved
V function, and transient AF.
The long-term outcome of AF presentation in ACS with
nd without ST-segment elevation was assessed in 120,566
atients (31) in a retrospective study of 10 randomized,
ontrolled trials. The overall prevalence of AF was 7.5% (8%
s. 6.4% in patients with versus without ST-segment eleva-
ion ACS, p  NS). Atrial fibrillation was associated with
2- to 4-fold risk for death, infarction, bleeding, and stroke
n both groups, similar to previous studies. Thus, AF
mplies excess risk of similar magnitude in ACS with or
ithout ST-segment elevation.
Another study reported the outcome of patients with AF
ndergoing cardiac resynchronization therapy (32); 438
atients were followed for 22 months after cardiac resyn-
hronization therapy. Sinus rhythm patients (n  337) had
etter survival than AF patients (n  146), despite His-
undle ablation or high atrioventricular block at the time of
mplantation.
Radiofrequency ablation of atrial flutter is a curative
rocedure but can be painful to the patient. Cryoablation is
new and pain-free technique. In a prospective, randomized
tudy, 154 patients with atrial flutter were randomly as-
igned to radiofrequency ablation or cryoablation with
-mm-tip ablation catheters (33). The end points were
cute and 3-month success rate and bidirectional conduc-
ion block on repeat electrophysiological studies. The acute
uccess rate was comparable between the groups (92.4% for
adiofrequency ablation and 93.4% for cryoablation). Five
elapses were observed in the cryoablation group and none
n the radiofrequency ablation group; the repeated electro-
hysiological studies showed bidirectional block in 84.9% of
he radiofrequency ablation group as compared with 63.5%
n the cryoablation group (p  0.05). Accordingly, radio-
requency ablation remains superior to cryoablation in the
reatment of atrial flutter.
The reliability and utility of remote transmissions of
ntracardiac electrocardiograms (ECGs) from implantable
ardioverter-defibrillators were assessed in 522 defibrillator oecipients followed for a mean of 303 days (34). The
ransmitted intracardiac ECGs were compared with intra-
ardiac ECGs interrogated from the device at the next
linical visit. During follow-up, 1,998 ventricular tachycar-
ia episodes and 488 ventricular fibrillation episodes were
ecorded in 198 patients. The success rate of transmitting
ntracardiac ECGs was 79% for slower and 65% for faster
entricular tachycardias; for ventricular fibrillation the suc-
ess rate was 76%.
alvular Heart Disease
number of abstracts focused on pathophysiology and
otential therapeutic options in calcified aortic stenosis
AS). Speidl et al. (35) studied AS in a rabbit model of
polipoprotein AI-Milano, a mutant form of apolipoprotein
I, that has previously been shown to cause regression of
stablished atherosclerotic lesions. Histology demonstrated
marked reduction in valve thickening and inflammatory
nfiltration in the treatment group, and Doppler echocardi-
graphy revealed a significant decrease in transvalvular
radient with an increase in valve area, whereas gradients
ncreased and valve areas decreased in the placebo group.
mlodipine significantly improved valve function and de-
reased lesion thickness, inflammation, and lipid infiltration
n an animal model of AS (36), and ramipril resulted in
significant retardation of functional deterioration and
orsening of endothelial function (37). Finally, beta
-adrenergic receptor agonists inhibit osteoblastic differen-
iation of human aortic valve interstitial cells, suggesting its
otential role in preventing valve calcification (38). Al-
hough these results are promising, they have to be viewed
ith caution, because previous experience showed the dif-
culties in translating experimental studies into the clinical
etting of AS.
A number of abstracts reported on predictors of outcome
nd their potential to improve patient management. Pa-
ients with severe AS were studied before and 9 months
fter aortic valve replacement with strain rate imaging and
agnetic resonance imaging (MRI) and had myocardial
iopsies taken during surgery (39). Postoperative functional
utcome was closely related to the extent of fibrosis on
ontrast-enhanced MRI. Preoperative longitudinal strain
as significantly lower in patients with poor post-operative
unctional class; importantly, pre-operative LVEF was nor-
al in the majority of patients and did not predict post-
perative outcome.
Valencia Serrano et al. (40) reported that the serum
oncentration of the carboxy-terminal propeptide of procol-
agen type I correlated well with myocardial fibrosis in AS
efined by the collagen volume fraction. Monin et al. (41)
onfirmed that BNP is an important predictor of outcome
n asymptomatic AS, and Bergler-Kein et al. (42) studied
NP in low-flow AS. The BNP was a potent predictor of
utcome in all subgroups. Most importantly, BNP 550
p
n
p
3
E
n
(
L
c
f
I
A
p
E
a
r
v
t
h
R
t
c
a
t
b
S
m
h
3
w
m
L
e
s
a
e
d
p
p
fi
r
t
t
o
(
G
M
e
0
p
d
s
h
t
a
m
t
P
b
h
n
t
u
b
w
c
u
a
w
m
n
o
i
c
s
a
1
a
d
C
m
a
u
s
m
e
p
W
f
C
c
s
m
t
M
m
r
i
p
p
a
p
a
2427JACC Vol. 50, No. 25, 2007 Kristensen et al.
December 18/25, 2007:2421–30 Highlights of the 2007 ESC Scientific Sessionsg/ml identified patients without contractile reserve but
evertheless good survival.
Bonan et al. (43) updated the promising experience with
ercutaneous aortic valve repair for AS in 175 patients. The
0-day mortality of 15% compared favorably with the
uroScore predicted operative mortality of 24%. Percuta-
eous mitral valve repair for functional mitral regurgitation
MR) with the MONARC system (Edwards Lifesciences
LC, Irvine, California), a device implanted into the
oronary sinus to reduce the annulus, was reported to be
easible and safe (44).
maging
variety of abstracts related to echocardiography in clinical
atient management were presented. According to recent
SC and ACC/AHA guidelines, the management of
symptomatic MR should integrate data on severity of
egurgitation, LV function, and feasibility to repair the
alve. The proximal isovelocity surface area method is
raditionally used to quantify MR, with the paradigm of a
emispheric flow convergence region and a constant orifice.
eal-time 3-dimensional (3D) echocardiography was used
o assess the true shape and potential variability of flow
onvergence regions; the vast majority were hemi-ellipsoid
nd not hemispheric, and 30 % were variable. A patient-
ailored algorithm was evaluated in a direct comparison
etween 2-dimensional (2D) and 3D echocardiography.
urprisingly, the 2D proximal isovelocity surface area
ethod remained superior over 3D, possibly related to the
igher spatial and temporal resolution (45).
Another study (46) presented the feasibility of a real-time
D transesophageal echocardiography with a matrix probe,
hich significantly improved visualization of valvular abnor-
alities and could facilitate planning of surgical valve repair.
ancellotti et al. (47) assessed various parameters (with 2D
chocardiography, tissue Doppler imaging, and 2D radial
train) at rest and during exercise in patients with severe
symptomatic MR and demonstrated that 2D strain at
xercise was the best predictor for development of LV
ysfunction over time.
Biagini et al. (48) reviewed echo-Doppler studies of 239
atients with hypertrophic cardiomyopathy over a follow-up
eriod of 10 8 years, to assess the importance of restrictive
lling (defined as E deceleration time 130 ms and E/A
atio 2). There were 39 cardiac deaths and 16 heart
ransplantations during follow-up; a restrictive filling pat-
ern was associated with an increased risk of (sudden) death
r transplantation.
Research in multidetector computed tomography
MDCT) was mainly focused on noninvasive angiography.
ilard et al. (49) evaluated the prognostic value of a normal
DCT. During a follow-up period of 14.7 months, the
vent death rate was 0%, whereas the infarction rate was
.7%. Noninvasive angiography with MDCT might be
articularly useful in high-risk asymptomatic populations to retect CAD. In 119 asymptomatic diabetic patients, 64-
lice MDCT detected atherosclerosis in 77%, with 27%
aving at least 1 significant stenosis (50). It was also shown
hat systemic inflammatory plasma markers are related to
therosclerosis on MDCT; in 230 individuals the inflam-
atory parameters IL-7 and -13 strongly correlated with
he presence of coronary artery calcium (51). Furthermore,
undziute et al. (52) performed a head-to-head comparison
etween MDCT and intravascular ultrasound with virtual
istology in patients with stable CAD and ACS. More
oncalcified plaques were observed on MDCT in ACS;
hese lesions had larger necrotic cores on intravascular
ltrasound with virtual histology, suggesting more vulnera-
le lesions. The main drawback to noninvasive angiography
ith MDCT remains the radiation dose. Conradi et al. (53)
ompared the effective dose in 210 patients, with 56
ndergoing 16-slice MDCT, 47 having 64-slice MDCT,
nd 107 undergoing dual-source CT. The effective doses
ere 9.76  1.84 mSv, 13.6  2.8 mSv, and 13.4  6.8
Sv, respectively, indicating no dose reduction with the
ewer scanners.
Various abstracts were presented on the prognostic value
f contrast-enhanced MRI. In 118 patients with chronic
schemic LV dysfunction, the extent of viability on
ontrast-enhanced MRI (defined as the segments with
car extending to 50% of the LV wall) predicted death
nd HF hospital stay independently from LVEF (54). In
05 consecutive patients with known or suspected CAD,
combination of dipyridamole stress perfusion and
elayed contrast-enhanced MRI was performed to detect
AD (55). From the MRI studies, rest and stress wall
otion were derived as well as stress perfusion defects, in
ddition to scar tissue. Invasive coronary angiography was
sed as the gold standard for CAD. Perfusion defects
eemed the most sensitive for detection of (particularly
ultivessel) CAD.
Novel work in nuclear cardiology was presented by Hyafil
t al. (56), who evaluated atherosclerotic aortic rabbit
laques with positron emission tomography (PET)-CT.
ith PET, imaging with F18-fluorodeoxyglucose was per-
ormed to detect metabolic activity in the aortic plaques.
o-registration with CT was performed, and a new CT
ontrast agent (N1177) was used that is formed of a
uspension of insoluble iodine molecules and is taken up by
acrophages. A correlation between contrast-enhanced ac-
ivity on CT and metabolic activity on PET was shown.
oreover, immunostaining of aortic cross-sections revealed
acrophage-rich areas correlating with the PET-CT active
egions. These preliminary findings suggest that molecular
maging with PET and CT contrast is feasible and might
otentially detect vulnerable lesions. Doue et al. (57) re-
orted on the use of technetium-99m annexin 5 (a tracer for
poptosis) in rabbits developing aortic atherosclerotic
laques on a high-cholesterol diet; significantly lower tracer
ctivity was observed in the plaques when these rabbits were
eceiving statin therapy.
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ore than 300 abstracts were presented in the topic group
Basic Science,” offering insights into mechanisms underly-
ng disease and identifying novel potential therapeutic
trategies. In the area of atherosclerosis the focus was on
laque stability and rupture. Kraaijeveld et al. (58) showed
n a molecular, cellular, and in vivo approach that disruption
f the myocyte-enhancer-binding-factor 2 gene leads to
ntraplaque bleeding. Donners and Waltenberger (59) used
yeast-2-hybrid screen to elucidate downstream mediators
f the vascular endothelial growth factor receptor signaling
athway that could serve as more specific therapeutic
argets. They identified a disintegrin and metalloprotease 10
s a novel potential target. A new approach for targeted
mmunocytokine therapy was presented by Dietrich et al.
60). Human IL-2 was targeted to active plaque via linking
o a single-chain antibody against extra domain-B–
bronectin, thereby locally activating regulatory T-cells and
ignificantly reducing plaque in the apolipoprotein E/
ouse. In vascular repair several studies investigated mech-
nisms of homing of endothelial progenitor cells. Limbourg
t al. (61) demonstrated the critical role of notch signaling
n this process. Wassmann et al. (62) showed that a
nockdown of the angiotensin type-1 receptor on bone
arrow–derived cells improves endothelial function, de-
reases macrophage infiltration of plaques, and reduces
therosclerosis in hypercholesterolemic apolipoprotein
/ mice, indicating that this receptor can contribute to
he atherosclerotic process.
Stromal-derived factor (SDF)-1 recruits and induces
ifferentiation of CD34 progenitor cells and can do so via
latelets (63). Segers et al. (64) sought to improve homing
f stem cells to the area of myocardial infarction with
DF-1 with a novel “peptide technology” developed for
ocal cartilage repair. They designed a metalloprotease-
esistant SDF-1 and linked it to RAD16-II, a so-called
elf-assembling peptide that forms nanofibers and hydrogel
t the place of injection, thereby potentially increasing and
rolonging the local effects of SDF-1. In a rat model of
yocardial infarction, the engineered peptides improved
unction and capillary density.
Other work examined the role of connective tissue
rowth factor in cardiac remodeling (65,66) with a trans-
enic mouse with a cardiac-restricted overexpression of this
rowth factor. Somewhat unexpectedly, this protein that is
nown to induce fibrosis in vitro actually prevented dilata-
ion and improved cardiac function after aortic banding and
ressure overload. The hearts were also protected during
schemia-reperfusion with a reduction of infarct size by
ore than 60%.
Looking for alternative ways to provide protection to the
schemic heart after reperfusion, Ghaleh et al. (67) demon-
trated that interrupting caspase-mediated cell death with
he recombinant protein BIR3/RING issued from the
-linked inhibitor of apoptosis protein, even at 3 h aftereperfusion, protects the myocardium against infarction.
abiker et al. (68) showed that protection offered by
acing-induced dyssynchrony during the early reperfusion
hase in isolated rabbit hearts relies on “classic” pathways.
Several studies reported on ways to improve stem cell
herapy and tissue regeneration. The role of micro-
ibonucleic acid in differentiation was highlighted by
luijter et al. (69). A study by van Vliet et al. (70) reported
hat hyperpolarization of adult cardiac stem cells in culture
peeded and improved differentiation toward a cardiac
henotype.
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